Compound optimization in early- and late-phase drug discovery: Acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 1, 2000, Pages 30-41

  Caldwell, Gary W ^a  

^a Pharmaceutical Research Institute   (United States)

Author keywords

adrenoceptor blockers; Assays; Bioavailability; Pharmacokinetics

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; TIMOLOL;

ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; PHARMACOKINETICS; PHYSICAL CHEMISTRY;

EID: 0033952168     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. DiMasi JA: Risks, regulation, and rewards in new drug development in the United States. Regul Toxicol Pharmacol (1994)19:228-235.
2. DiMasi JA: Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther (1995) 58:1-14.
3. Kennedy T: Managing the drug discovery/development interface. Drug Disc Today (1997) 2:436-444.
4. A good review of the skill sets necessary to manage an interface between discovery and development.
5. Caldwell J: The importance of drug metabolism studies for efficient drug discovery and development Yakubutsu Dotai (1996)11(1):119-126.
6. Caldwell GW: Novel biophysical analytical methods: The utility of combining physicochemical and In vitro physiological proprieties of drug compounds for estimating In vivo oral bioavailability. Second International Symposium on Drug-Drug Interaction Potential. Baltimore, MD, USA (1997).
7. Benet LZ, Mitchell JR, Sheiner LB: Goodman and Oilman's The Pharmacological Basis of Therapeutics. 8th Edition. Oilman AG, Rail TW, Nies AS, Taylor P (Eds), Pergamon Press, New York (1990):1-62.
8. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P: P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol 77ier(1998) 36:16-24.
9. Lewis DF (Ed): Cytochromes P450: Structure, Function and Mechanism. Taylor & Francis Ltd, London (1996):1-348.
10. Reif OW, Lausch R, Freitag R: High-performance capillary electrophoresis of human serum and plasma proteins. Adv Chromatogr(1994) 34:1-56.
11. Heykants J, Meuldermans W: Nonclinical kinetics and metabolism studies in support of the safety assessment of drugs. Drug InfJ (1994) 28:163-172.
12. A good review of the studies necessary for preclinical and clinical toxicology.
13. Rodrigues AD: Use of in vitro human metabolism studies in drug development An industrial perspective. Biochem Pharmacol (1994) 48(12):2147-2156.
14. Rodrigues AD: Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm Res (1997) 14(11 ):1504-1510.
15. A good review of some of the potential problems encountered in preclinical drug metabolism and rational screening strategies.
16. Rodrigues AD: Rational high-throughput screening in preclinical drug metabolism. Mea Chem Res (1998) 8(7/8):422-433.
17. Tarbit MH, Bemnan J: High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr Opin Chem Biol (1998) 2:411-416.
18. Smith DA, van de Waterbeemd H: Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol (1999)3:373-378.
19. Sinko PJ: Drug selection in early drug development: Screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr Opin Drug Discovery Dev (1999) 2(1 ):42-48.
20. Benton D: Integrated access to genomic and other bioinformation: an essential ingredient of the drug discovery process. SAR QSAR Environmental Research (1998)8(3-4):121-155.
21. Broach JR, Thorner J: High-throughput screening for drug discovery. Nature (1996) 384:14-16.
22. Silverman L, Campbell R, Broach JR: New assay technologies for high-throughput screening. Curr Opin Chem Biol (1998) 2:397-403.
23. Mere L, Bennett T, Coassin P, England P, Hamman B, Rink T, Zimmerman S, Negulescu P: Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening. Drug Disc Today (1999) 4(8):363-369.
24. Winkler T, Kettling U, Koltermann A, Eigen M: Confocal fluorescence coincidence analysis: an approach to ultra high-throughput screening. Proc Natl Acad Sci USA (1999) 96(4):1375-1378.
25. An interesting paper outlining an approach to screen 100,000 compounds/day.
26. Fecik RA, Frank KE, Gentry EJ, Menon SR, Mitscher LA,. Telikepalli H: The search for orally active medications through combinatorial chemistry. MedRes Rev(1998) 18:149-185.
27. A good review of combinatorial chemistry with ideas concerning the incorporation of ADME properties in the design of libraries.
28. Stanton DT, Morris TW, Roychoudhury S, Parker CN: Application of nearest-neighbor and cluster analyses in pharmaceutical lead discovery. J Chem Inf Comput Sci (1999) 39(1 ):21-27.
29. de Julian-Ortiz JV, Galvez J, Munoz-Collado C, GarciaDomenech R, Gimeno-Cardona C: Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. J Med Chem (1999) 42(17):3308-3314.
30. Ekins S, Bravi G, Binkley S, Giucspie JS, Ring BJ, Wikel JH, Wrighton SA: Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Phamacogenetics (1999) 9(4):477-489.
31. Wang J, Ramnarayan K: Toward designing drug-like libraries: A novel computational approach for prediction of drug feasibility of compounds. J Combinatorial Chem (1999) 1(6):524-533.
32. Bohm H-J: Computational tools for structure-based ligand design. Prog Biophys Mol Blol (1996) 66(3):197-210.
33. Gerhold D, Rushmore T, Caskey CT: DNA chips: promising toys have become powerful tools. Trends Biochem Sci (1999)24(5):168-173.
34. Johnson DE, Braeckman RA, Wolfgang GH: Practical aspects of assessing toxlcokinetics and toxicodynamics. Curr Opin Drug Discovery Dev (1999) 2(1):49-57.
35. Todd MD, Ulrich RG: Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr Opin Drug Discovery Dev (1999) 2(1):58-68.
36. Wildman SA, Grippen GM: Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci (1999)39(5):868-873.
37. Huuskonen J, Salo M, Taskinen J: Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J Chem Inf Comput Sci (1998) 38(3):450-456.
38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug -discovery and development setting. Adv Drug Detiv Rev (1997) 23:3-25.
39. Stenberg P, Luthman K, Ellens H, Lee CP, Smith PL, Lago A, Elliott JD, Artursson P: Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm Res (1999) 16(10):1520-1526.
40. Erhardt PW: Drug metabolism data: Past and present status. Med Chem Res (1998) 8:400-421.
41. Cronin MT: Computer-aided prediction of drug toxicity in high throughput screening. Pharm Pharmacol Commun (1998)4:157-163.
42. Kansy M, Senner F, Gubemator K: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem (1998) 41 (7): 1007-1010.
43. Plumb JA: Cell sensitivity assays: the MTT assay. Methods Mol Med (1999) 8(Cytotoxic drug resistance mechanisms):25-30.
44. Caldwell GW, Masucci JA, Chacon E: High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb Chem High-Throughput Screen (1999) 2(1 ):39-51.
45. Van Breemen RB, Nikolic D, Bolton JL: Metabolic screening using on-line Ultrafiltration mass spectrometry. Drug Metab Dispos (1998) 26(2):85-90.
46. An interesting approach for doing online drug metabolism.
47. Nikolic D, Fan PW, Bolton JL, Van Breemen RB: Screening for xenobiotic electrophilic metabolites using pulsed ultrafiltration-mass spectrometry. Comb Chem High-Throughput Screen (1999) 2(3):165-175.
48. Crespi CL, Miller VP, Penman BW: Micro t it er plate assays for Inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem (1997) 248(1):188-190.
49. Crespi CL: Higher-throughput screening with human cytochromes P450. Curr Opin Drug Discovery Dev (1999) 2(1):15-19.
50. Crespi CL, Miller VP, Penman BW: High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res (1998) 8(7/8):457-471.
51. An outstanding paper for screening the inhibition of P450 metabolism.
52. Avdeef A, Box KJ, Comer JE, Güges M, Hadley M, Hibbert C, Patterson W, Tarn KY: pH-Metric log P 11. pK. determination of water-insoluble drugs In organic solvent-water mixtures. J Pharm Biomed Anal (1999) 20(4):631-641.
53. Takacs-Novak K, Avdeef A: Interlaboratory study of log P determination by shake-flask and potentiometric methods. J Pharm Biomed Anal (1996) 14(11):1405-1413.
54. Avdeef A: pH-Metric solubility. 1. Solubility-pH profiles from Bjerrum plots. Gibbs buffer and pK. in the solid state. Pharm Pharmacol Comm (1998) 4(3):165-178.
55. Avdeef A, Box KJ, Comer JE, Hibbert C, Tarn KY: pH-Metric logP 10. Determination of liposomal membrane-water partition coefficients of lonizable drugs. Pharm Res (1998) 15(2):209-215.
56. Yang CY, Cai SJ, Liu H, Pidgeon C: Immobilized artificial membranes - screens for drug-membrane interactions. Adv Drug Deliv Rev (1997) 23(1-3):229-256.
57. Caldwell GW, Masucci JA, Evangelisto M, White R: Evaluation of the immobilized artificial membrane phosphatidylcholine. Drug discovery column for highperformance liquid Chromatographie screening of drugmembrane interactions. J ChromatogrA (1998) 800(2):161-169.
58. Ducarne A, Neuwels M, Goldstein S, Massingham R: IAM retention and blood brain barrier penetration. Eur J Med Chem (1998) 33:215-223.
59. Masucci JA, Caldwell GW, Foley JP: Comparison of the retention behavior of -blockers using immobilized artificial membrane chromatography and lysophospholipid micellar electrokinetic chromatography. J Chromatogr A (1998)810(1-2):95-103.
60. Yee S: In vitro permeability across Caco-2 cells (colonie) can predict in vivo (small intestinal) absorption in man fact or myth. Pharm Res (1997) 14(6):763-766.
61. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sc/(1999) 88(1):28-33.
62. Caldwell GW, Easlick SM, Gunnel J, Masucci JA, Demarest K: In vitro permeability of eight -blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom (1998) 33(7):607-614.
63. McDonnell PA, Caldwell GW, Masucci JA: Using capillary electrophoresis/frontal analysis to screen drugs interacting with human serum proteins. Electrophoresis (1998)19(3):448-454.
64. Mattes WB, Li AP: Quantitative reverse transcriptase/PCR assay for the measurement of induction In cultured hepatocytes. Chem Biol Interact (1997) 107:47-61.
65. Sanwald-Ducray P, Dow J: Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro/in vivo and interspecies allometric scaling. Xenobiotica (1997) 27(2):189-201.
66. Olah TV, McLoughlin DA, Gilbert JD: The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom (1997) 11:17-23.
67. Bayliss MX, Frick LW: High-throughput pharmacokinetics: Cassette dosing. Curr Opin Drug Discovery Dev (1999) 2(1):20-25.
68. Wong PS, Yoshioka K, Xie F, Kissinger PT: In vivo microdialysis/liquid chromatography/tandem mass spectrometry for the on-line monitoring of melatonin in rat. Rapid Commun Mass Spectrom (1999) 13(5):407-411.
69. Masucci JA, Ortegon ME, Jones WJ, Shank RP, Caldwell GW: In vivo microdialysis and liquid chromatographyl thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-O-(1 -methylethylidene)-β-D-fructopyranose sulfamate (topiramate) in rat brain fluid. J Mass Spectrom (1998) 33(1):85-88.
70. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, Ranee DJ, Wastall P: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. JPharmacolExp Ther(-\997) 283(1 ):46-58.
71. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson ÇA, Sugiyama Y: Prediction of In vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol T/7er(1997) 73(2):147-171.
72. Houston JB, Carlile DJ: Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev (1997)29(4):891-922.
73. Meier J: Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J (1982) 104(2):364-373.
74. Hinderung PH, Schmidlin O, Seydel JK: Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. J Pharmacokinet Biopharm (1984) 12(3):263-287.